الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 58 |  |  |
| | | from | 58 | | |
Abstract
Corona virus disease spread rapidly all over the world and became a global epidemic, and millions of cases were reported in a short period, as well as a large number of deaths, as confirmed by the World Health Organization.
COVID-19 can cause symptoms that range from mild to very severe. Most patients have mild infections and can recover within weeks. Those with clinical manifestations of pneumonia, respiratory failure, and acute respiratory distress syndrome require hospitalization.
The World Health Organization has revealed that tocilizumab is allowed to be used to treat severe cases of COVID 19.
Tocilizumab has been monoclonal antibody, it inhibits interleukin-6receptor, and interleukin-6 stimulates the inflammatory response & is showed at high levels in studied cases with severe symptoms of COVID 19.
According to studies, tocilizumab lowers mortality in some COVID 19 studied cases who are critically ill, fast worsening, need more oxygen, & are experiencing substantial inflammatory response.
Therefore, goal of the work had been to study impact of tocilizumab on critically ill studied cases with Covid19.
In the current study, eighty patients in critical care units at Alexandria University Hospitals suffered from acute pneumonia as result of infection with covid 19.
Following data were recorded: patient admission criteria, patient clinical criteria, and laboratory criteria.
Tocilizumab was given to patients who were confirmed with Covid 19 and suffered from severe pneumonia in the 1st 2 days of referral to icu .
After follow-up and evaluation of the patients’ condition after administration of tocilizumab, the following results were obtained:
There is no statistical significance between before and after administration of tocilizumab with respect to inflammatory markers, including C-reactive protein.
Our present findings clearly revealed that there had been non-statistically significant variation among before & after administration of tocilizumab with respect to IL6. There were 51 (58%) improved and 37 (42%) increased with a mean decrease of -91.02.
There is a statistical indication that tocilizumab may have some beneficial effect by reducing need for respiratory support in studied cases with Covid-19 and reducing their need for a penetrating respiratory system.
There is no statistical significance between before and after administration of tocilizumab with regard to survival in intensive care and mortality. However, some studies showed that the use of tocilizumab may have a relationship with reducing the survival time and the patient’s need for intensive care.